Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05992480 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

REVIVE (Response to the Ebola Virus Vaccine)

StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: May 2026 to Nov 2026
    • Site details revised
    v7
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2025 to Dec 1, 2025
    • Site details revised
    v6
  3. Start date: May 2025 to Sep 2025
    • Primary completion date: Jan 2026 to May 2026
    • Study completion date: Feb 2026 to May 2026
    v5
  4. Primary completion date: Jul 1, 2025 to Jan 2026
    • Start date: Jan 6, 2025 to May 2025
    • Study completion date: Aug 30, 2025 to Feb 2026
    v4
  5. Start date: Aug 15, 2024 to Jan 6, 2025
    • Primary completion date: Mar 1, 2025 to Jul 1, 2025
    • Study completion date: Mar 1, 2025 to Aug 30, 2025
    v3
  6. Primary completion date: Jun 15, 2024 to Mar 1, 2025
    • Start date: Jan 15, 2024 to Aug 15, 2024
    • Study completion date: Jun 30, 2024 to Mar 1, 2025
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a vaccine-related clinical trial which will be conducted by our study team at Kenema Government Hospital (KGH)'s Viral Hemorrhagic Fever Program in collaboration with Tulane University School of Medicine. This study is funded by Merck \& Co., the developers of ERVEBO®. This investigational medicinal product (IMP) was successful in Sierra Leone through the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE) working with the College of Medical and Allied Health Services (COMAHS) at the University of Sierra Leone. ERVEBO® was also successfully tested in Liberia and the Republic of Guinea. These successful trials led to the United States Food and Drug Administration (USFDA) approval of ERVEBO®, as well as approval for therapeutic use in the Democratic Republic of the Congo, Burundi, Ghana, and Zambia. This particular vaccination study will focus on the anamnestic response to the ERVEBO® vaccine, (full name - rVSVDG-ZEBOV-GP Ebola Virus Vaccine). The original clinical trials conducted excluded Ebola Virus Disease (EVD) survivors from participating. However, with ongoing research, there is evidence of waning immune response and even recurrent infections in EVD survivors.
Trial Details
NCT Number NCT05992480
Lead Sponsor Tulane University
Collaborators: Kenema Government Hospital, Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Ebola Virus Disease
Related terms Hemorrhagic Fever, Ebola
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov